Intensity Therapeutics (INTS) announces that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor. In a study conducted in the Staedtke-Bai laboratory at Johns Hopkins University, at 21 days, animals tested with INT230-6 all achieved a complete response, whereas all animals’ tumors in the control group continued to grow.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks